The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Clinical Pharmacokinetics of Intranasal Sumatriptan
Abstract
A substantial proportion of migraine patients have gastric stasis and suffer severe nausea and/or vomiting during their migraine attack. This may lead to erratic absorption from the gastrointestinal tract and make oral treatment unsatisfactory. For such patients, an intranasal formulation may be advantageous. Sumatriptan is a potent serotonin 5HT(1B/1D) agonist widely used in the treatment of migraine; the effectiveness of the intranasal formulation (20mg) has been well established in several clinical studies. This article reviews the pharmacokinetics of intranasal sumatriptan and includes comparisons with oral and subcutaneous administration. After intranasal administration, sumatriptan is directly and rapidly absorbed, with 60% of the maximum plasma concentration (C(max)) occurring at 30 minutes after administration of a single 20mg dose. Following intranasal administration, approximately 10% more sumatriptan is absorbed probably via the nasal mucosa when compared with oral administration. Mean C(max) after a 20mg intranasal dose is approximately 13.1 to 14.4 ng/mL, with median time to C(max) approximately 1 to 1.75 hours. When given as a single dose, intranasal sumatriptan displays dose proportionality in its extent of absorption and C(max) over the dose range 5 to 10mg, but not between 5 and 20mg for C(max). The elimination phase half-life is approximately 2 hours, consistent with administration by other routes. Sumatriptan is metabolised by monoamine oxidase (MAO; predominantly the A isozyme, MAO-A) to an inactive metabolite. Coadministration with a MAO-A inhibitor, moclobemide, leads to a significant increase in sumatriptan plasma concentrations and is contraindicated. Single-dose pharmacokinetics in paediatric and adolescent patients following intranasal sumatriptan were studied to determine the effect of changes in nasal morphology during growth, and of body size, on pharmacokinetic parameters. The pharmacokinetic profile observed in adults was maintained in the adolescent population; generally, factors such as age, bodyweight or height did not significantly affect the pharmacokinetics. In children below 12 years, C(max) is comparable to that seen in adolescents and adults, but total exposure (area under the concentration-time curve from zero to infinity) was lower in children compared with older patients, especially in younger children treated with 5mg. Clinical experience suggests that intranasal sumatriptan has some advantages over the tablet (more rapid onset of effect and use in patients with gastrointestinal complaints) or subcutaneous (noninvasive and fewer adverse events) formulations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Discussions with neurologists in the drafting of this review indicated that the improper administration of nasal triptans may account for their seeming ineffectiveness.66”
Citations
Cites
(1976) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1976.tb115280.x · Cited by 5,237
Treatment of Migraine Attacks with Sumatriptan
The Subcutaneous Sumatriptan International Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250504 · Cited by 448
Ferrari, M. D. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11370-8 · Cited by 387
McMartin, C., Hutchinson, L. E. F., Hyde, R., & Peters, G. E. (1987) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600760709 · Cited by 349
Treatment of Acute Migraine With Subcutaneous Sumatriptan
Cady, R. K. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460210077033 · Cited by 318
(1977) · Food and Cosmetics Toxicology · doi:10.1016/s0015-6264(77)80400-8 · Cited by 302
Winner, P., Rothner, A. D., Saper, J., Nett, R., Asgharnejad, M., Laurenza, A., Austin, R., & Peykamian, M. (2000) · Pediatrics · doi:10.1542/peds.106.5.989 · Cited by 281
Treatment of migraine attacks with sumatriptan
Milne, L. (1992) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(92)90247-q · Cited by 252
The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan
Fowler, P. A., Lacey, L. F., Thomas, M., Keene, O. N., Tanner, R. J. N., & Baber, N. S. (1991) · European Neurology · doi:10.1159/000116756 · Cited by 244
Research works printed but not linked: 8
- Dixon, 1993, Drug Metab Dispos, 21, 761
- Su, 1996, Drug Metab Dispos, 24, 884
- Christensen, 2000, Clin Pharmacol Ther, 67, 103
- Barrow, 1997, Biopharm Drug Dispos, 18, 443, 10.1002/(SICI)1099-081X(199707)18:5<443::AID-BDD35>3.0.CO;2-D · doi:10.1002/(sici)1099-081x(199707)18:5<443::aid-bdd35>3.0.co;2-d
- Wang, 1998, Biopharm Drug Dispos, 19, 571, 10.1002/(SICI)1099-081X(199812)19:9<571::AID-BDD142>3.0.CO;2-O · doi:10.1002/(sici)1099-081x(199812)19:9<571::aid-bdd142>3.0.co;2-o
- Moore, 2001, Cephalalgia, 21, 533
- Williams, 1997, Cephalalgia, 17, 417
- Williams, 1997, Cephalalgia, 17, 408
Cited by
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults
Fernandez, E., Perez, R., Hernandez, A., Tejada, P., Arteta, M., & Ramos, J. T. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3010053 · Cited by 370
“Some drugs that have been tested intranasally in children are midazolam, fentanyl, butorphanol, ketamine, sufentanil, corticosteroids, antihistamines, sumatriptan and desmopressin [27-31].”
BackgroundIntranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules
Fortuna, A., Alves, G., Serralheiro, A., Sousa, J., & Falcão, A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.03.004 · Cited by 211
Puledda, F., Sacco, S., Diener, H., Ashina, M., Al‐Khazali, H. M., Ashina, S., Burstein, R., Liebler, E. J., Cipriani, A., Chu, M. K., et al. (2024) · Cephalalgia · doi:10.1177/03331024241252666 · Cited by 159
“Intranasally administered sumatriptan, zolmitriptan, zavegepant or DHE are good alternatives as they mostly by-pass abdominal absorption (132).”
Venkatesan, T., Levinthal, D. J., Tarbell, S. E., Jaradeh, S. S., Hasler, W. L., Issenman, R. M., Adams, K. A., Sarosiek, I., Stave, C. D., Sharaf, R. N., et al. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13604 · Cited by 137
Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting
Vyas, T. K., Babbar, A. K., Sharma, R. K., & Misra, A. R. (2005) · Journal of drug targeting · doi:10.1080/10611860500246217 · Cited by 114
“T h e p h a rm a co k in et ic p a ra m et er s a re d er iv ed u si n g m ea n ^ S E M o f fo u r es ti m a ti o n s. transport of drugs to the brain (Behl et al. 1998, IIIlum 2000, Fuseau et al. 2002).”
Metadata
- Authors
- Fuseau, E., Petricoul, O., Moore, K. H., Barrow, A., & Ibbotson, T.
- Affiliations
- Sciences Po Aix (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Moore, Katy HP
- ORCID
- Ibbotson, Tim
- Venue
- Clinical Pharmacokinetics
- Published
- 2002
- Volume
- 41
- Issue
- 11
- Pages
- 801-811
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W1983027274
- Cited by
- 69
- References
- 0
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 4 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 6
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- sumatriptan, intranasal administration, pharmacokinetics, migraine, nasal absorption, dose proportionality, elimination half-life, monoamine oxidase A, moclobemide, drug-drug interactions, pediatric pharmacokinetics, adolescents, gastric stasis, bioavailability, subcutaneous administration
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Animals, Child, Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Interactions, Humans, Kidney Diseases, Liver Diseases, Migraine Disorders, Serotonin Receptor Agonists, Sumatriptan
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacokinetics of Intranasal Sumatriptan. https://app.cochat.ai/papers/10.2165/00003088-200241110-00002
- The paper
- Fuseau, E., Petricoul, O., Moore, K. H., Barrow, A., & Ibbotson, T. (2002). Clinical Pharmacokinetics of Intranasal Sumatriptan. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200241110-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.